Accelerate to discover

Back to filter

Related topics

Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin

IZON

May 4, 2022

Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...

Why use Cytek Aurora?

Cytek Biosciences

May 3, 2022

A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Introducing IsoPlexis Single-Cell Natural Killer Panel

IsoPlexis

Mar 4, 2022

Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...

May 22, 2022

Enhanced small particle detection on CytekAurora and Northern Lights

Cytek Biosciences

Mar 2, 2022

Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...

Multi-modal PET drives interdisciplinary preclinical imaging

Bruker Biospin

Feb 23, 2022

Preclinical imaging (PCI) plays a vital role in understanding the biological processes behind disease states at the...

Quantitative 3D Optical Imaging for Lago

Spectral Instruments Imaging

Feb 21, 2022

Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...

May 22, 2022

Reduces fMRI-BOLD Response in the Brain

Bruker Biospin

Feb 18, 2022

fMRI studies often involve the electrical stimulation of i.e. the forepaw, detecting where this stimulation is...

Show all topics (10)

Insulin receptor substrate 1 is a substrate of the Pim protein kinases

May 18, 2020

The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates.

Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.

Do you want to learn more? Read the whole article!

Scientific paper
Application

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Spectral Instruments Imaging

Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Related products

System for individual researchers and smaller specialist teams to conduct optical imaging studies in disease model progression, response to therapy, and cell migration in-vivo.

show detail

The Ami HT and Ami HTX (includes X-Ray imaging) optical imaging systems establish a new, high throughput benchmark for in vivo imaging suitable for specialist researchers and small teams.

show detail

The Lago and X‐Ray capable Lago X optical imaging systems provide a powerful and flexible in-vivo imaging capability suitable for imaging cores, specialist researchers and small teams, delivering an unmatched 10 mouse capacity across BLI, FLI and X‐Ray.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey